Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec 14;6:627. doi: 10.3389/fimmu.2015.00627

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Shen, Sanchez, Zan and Casali.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

HDI selectively inhibits miRNA expression in B cells induced to undergo CSR and plasma cell differentiation. B cells were cultured with LPS plus IL-4 in the presence of HDI (VPA, 500 μM) or nil for 60 h before preparation of RNA for miRNA-Seq. (A) Scatter plots of average (in three independent experiments) miRNA expression levels (RPMs) in B cells treated with HDI versus that in B cells treated with nil. P values, paired t-test. (B) Bar graphs depict the changes of folds of the average miRNA expression levels (RPMs) in B cells treated with HDI as compared to that in B cells treated with nil. (C) Bar graphs depict the changes of folds of miRNA expression levels (RPMs) in B cells treated with HDI as compared to that in B cells treated with nil, in three independent experiments. (D) Scatter plots of miRNA expression levels in B cells treated with HDI versus those in B cells treated with nil, in three independent experiments. Only the miRNAs at average RPM > 0.5 in LPS plus IL-4-stimulated B cells treated with nil are included.